Additionally, the assay has been criticized for its low correlation with other antioxidant assays, such as FRAP and DPPH, which can lead to inconsistent findings (Christodoulou et al., 2022)
29 However, a recent study that showed a significant difference in the profiles of reporting risk and time-to-onset during the treatment with semaglutide or liraglutide, underlines that individual treatment choices should be considered when choosing an agent among GLP-1 analogues
The first is if youre experiencing any persistent abdominal pain (especially if it radiates to your back), vomiting that persists for longer than a day, or signs of dehydration like dizziness or markedly reduced urination
The study, published in the Journal of Clinical Investigation Insight , showed that each time overweight mice stopped and restarted GLP-1s, they dropped less and less weight compared their original weight-loss